Develops a therapy that induces transplantation tolerance, allowing kidney transplant recipients to live without lifelong immunosuppressive medications. This approach reduces the risk of rejection, improves long-term organ function, and enhances patient quality of life by eliminating the side effects and complications associated with immunosuppression.
Funding
$207M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Kidney transplant recipients face a lifetime of immunosuppressive medications to prevent organ rejection, leading to significant side effects, increased risk of infection, and potential long-term complications that negatively impact their health and quality of life. The need for continuous immunosuppression also affects the transplanted organ, potentially reducing its long-term function and lifespan.
Solution
ITB-MED is developing a novel therapy designed to induce transplantation tolerance, potentially eliminating the need for lifelong immunosuppressive drugs in kidney transplant recipients. This approach aims to allow patients to live healthier lives without the burden of immunosuppression, reducing the risk of rejection and improving long-term organ function. By achieving immunosuppression freedom, the therapy seeks to enhance patient quality of life and reduce associated healthcare costs.
Target Audience
The primary target audience includes kidney transplant recipients and healthcare providers specializing in transplantation medicine.
Features
- Induction of transplantation tolerance to eliminate the need for immunosuppressive medications.
- Improved long-term organ function and lifespan.
- Reduced risk of rejection episodes.
- Enhanced patient quality of life by avoiding side effects of immunosuppression.